AbbVie Ends Partnership With BioArctic in Parkinson’s Disease
Summary : AbbVie has terminated its collaboration agreement with BioArctic in the development of alpha-synuclein antibodies for Parkinson’s disease and other movement…
Summary : AbbVie has terminated its collaboration agreement with BioArctic in the development of alpha-synuclein antibodies for Parkinson’s disease and other movement…
Synopsis : Valneva’s single-shot chikungunya vaccine candidate, VLA1553, offered a very high level of seroprotection in all adults, including the elderly. The…
Summary : AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at…
Summary : British biotech company Scancell has expanded its research and development capabilities at one of the UK’s leading parks for science…
Summary : The Committee for Medicinal Products for Human Use (CHMP) has provided an initial assessment of Valneva’s inactivated, adjuvanted COVID-19 vaccine…
Summary : Chicago-based AbbVie has been making major decisions with company-wide impacts. The therapeutic company appears to be making changes that will…
Summary : Moderna is poised to begin Phase III of its pivotal clinical trial for its candidate vaccine for respiratory syncytial virus…
Summary : At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business,…
Synopsis : Malvern Panalytical, a company providing advanced analysis and services solutions for the pharma drug product development, as well as services…
Synopsis : Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today…